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Abstract 
Background and aims: Cardiovascular disease is the main complication and cause of 
morbidity and mortality in type 2 diabetes mellitus (T2DM) patients. The main cause of 
complication in T2DM is oxidative stress caused by insulin resistance, hence it can 
increase lipid profiles (cholesterol, LDL, and triglycerides) which exacerbates 
endothelial dysfunction. Among various functional foods with antioxidant effects, 
probiotic foods have been reported to suppress oxidative stress, and also improve the 
fasting blood glucose (FBG) and lipid profile in patients with T2DM. The aim of this 
clinical trial is to study the effects of probiotics and conventional yogurt on FBG and 
lipid profile in patients with T2DM. Material and method: Thirty-eight patients with 
T2DM, aged 30 to 60 years old, were assigned to two groups in this randomized, double-
blind, controlled clinical trial. The subjects in the intervention group consumed 100 
ml/day probiotic yogurt containing Lactobacillus acidophilus La-5 and Bifidobacterium 
lactis BB-12, whereas subjects in the control group consumed 100 ml/day conventional 
yogurt for four weeks. Anthropometric indices, dietary intake, physical activity, serum 
FBG, and lipid profile were evaluated at the beginning and end of the intervention. 
Results: Consumption of 100 mL/day conventional yogurt could significantly reduce the 
fasting blood glucose (FBG) level, whereas probiotic yogurt could not reduce FBG 
significantly. Although the total cholesterol and triglyceride were not improved after 
yogurt consumption, both type of yogurt could improve HDL-C level. Conclusion: Both 
conventional yogurt or probiotic yogurt could be used as functional food since it 
improved the HDL-C in type 2 DM patients. 
key words: conventional yogurt, probiotic yogurt, Lactobacillus acidophilus La-5, 
Bifidobacterium lactis BB-12 
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Background and aims 
Diabetes mellitus (DM) is a group of 
metabolic diseases characterized by 
hyperglycemia that occur due to abnormal 
insulin secretion, insulin action or both. In 
Indonesia, type 2 DM is one of the top ten 
causes of death due to non-communicable 
diseases. In 2020, type 2 DM is also estimated to 
be a disease with the highest increase in 
economic burden in Indonesia [1]. Various 
complications can occur in type 2 DM patients, 
one of them is caused by the conditions of poor 
blood glucose control (hyperglycemia) [2].  
Insulin resistance in type 2 DM patients 
causes changes in lipid profiles characterized by 
elevated total cholesterol, triglycerides, LDL-C 
levels, and decreased HDL level. This can cause 
endothelial dysfunction since LDL is 
atherogenic, easily adheres to blood vessel walls 
and binds cholesterol, whereas HDL have anti-
atherogenic, anti-oxidative, anti-inflammatory 
and anti-apoptotic effects. Decreased HDL level 
is caused by impaired HDL metabolism due to 
insulin resistance [3,4]. Endothelial dysfunction 
is also influenced by TRL (triglycerides-rich 
lipoprotein) which passes through endothelial 
cells and is taken by macrophages, which can 
form foam cells causing a continuous formation 
of fat [5]. 
Cardiovascular disease in type 2 DM 
patients is caused by conditions of 
hyperglycemia. Continuous hyperglycemia is 
closely related to abnormalities of lipid 
metabolism (dyslipidemia) so that it can cause 
endothelial damage [6-8]. In addition, changes in 
lipid absorption in the intestinal tract cause high 
cholesterol synthesis which increases the risk of 
cardiovascular disease [9]. 
Food containing probiotics can be used as 
secondary prevention of complications of type 2 
DM which is being investigated by Ejtahed et al. 
[6] and Rezaei et al. [10]. A study conducted by 
Ejtahed et al., [6], showed that administration of 
probiotics in the form of probiotic yogurt 
products can reduce oxidative stress. 
Consequently, fasting blood glucose (FBG) and 
fasting insulin level of type 2 DM patient can 
decrease. Some strains of lactic acid bacteria can 
act as antioxidants and reduce oxidative stress. 
Probiotic yogurt can increase the concentration 
of HDL-C as a result of the content of 
sphingolipid in the milk as the basic ingredient 
of yogurt and the sphingolipid in cell membranes 
of probiotic bacteria. Sphingolipid has an 
influence on cholesterol metabolism and 
transportation which later also affects HDL 
metabolism [11,12]. Other bacteria such as the 
combination of Lactobacillus acidophilus and 
Bifidobacterium lactis have also been studied 
and it can reduce cardiovascular biomarkers in 
people with type 2 DM. However, in several 
studies, this combination has not been proven 
effective in reducing cardiovascular biomarkers 
(LDL, triglycerides, and total cholesterol) and 
requires further research [6,13]. 
Most of probiotic yogurt studies in type 2 
DM gave probiotic yogurt at a dose of 300 
mL/day to the subjects. In the other hand, 
consumption of milk and its products are low 
among Indonesian society. Hence, in this study 
the subjects only given 100 mL/day probiotic 
yogurt. According to a study conducted by 
Yerlikaya [14], probiotic yogurt has a health 
effect at a dose of 100 mL with the content of 
bacterial amount of 106-108 CFU/mL. Therefore, 
taking into account the characteristic of 
Indonesian people who have low levels of yogurt 
consumption, we were interested in examining 
the effectiveness of giving probiotic yogurt 
(containing Lactobacillus acidophilus La-5 and 
Bifidobacterium lactis BB-12) and conventional 
yogurt at a dose of 100 mL/day (bacterial count 
> 106 CFU/mL) on the FBG, total cholesterol, 
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LDL, HDL, and triglycerides level of type 2 DM 
patients. 
Material and methods 
Study Design 
The design of this study was a randomized 
controlled trial (RCT) with a pre-post test group 
design. This study was began by the production 
of probiotic yogurt which contain Lactobacillus 
acidophilus La-5 as much as 108 CFU/gram and 
Bifidobacterium lactis BB-12 as much as 106 
CFU/gram. The conventional yogurt contained 
yogurt starter cultures namely Streptococcus 
thermophilus and Lactobacillus bulgaricus [10]. 
Subjects 
This clinical trial was carried out on diabetic 
patients who visited Puskesmas or primary 
health care in Yogyakarta, Indonesia during 
March 2018 until June 2018. The participants 
were chosen through reviewing medical records 
filed in the primary health care. The eligible 
patients were contacted and invited to participate 
in the study. 
The standard sample size was calculated 
using the formula hypothesis testing for two 
populations means from Lemeshow et al. [15], 
which considering the previous research by 
Rezaei et al. [10]. The number of subjects 
needed based on these calculations was 16 
patients each group or 32 patients in total for this 
study. Considering there might be drop out 
during the study, we added a 20% of subjects 
hence 38 peoples were enrolled for this study.  
The inclusion criteria were 1) diagnosed 
with type II diabetes in the aged between 30-65 
years old; 2) fasting blood glucose more than 
126 mg/dL; 3) consumption of glucose lowering 
drugs such as Glibenclamide or Metformin; 4) 
Not taking statin or cholesterol-lowering drugs; 
5) not taking antibiotic during the study and a 
month before this study began; 6) have a 
refrigerator; 7) ability to follow the treatment 
regimen and collaborate with the researchers. 
The exclusion criteria were 1) diagnosed with 
any complications (except hypertension and 
dyslipidemia); 2) lactose intolerance; 3) 
pregnancy and breastfeeding; 4) consuming any 
probiotic products for 2 weeks before this study 
began. The drop-out criteria were diagnosed any 
complications during this study, diarrhea, and 
consumption of antibiotic during the study. 
Before beginning of the study, patient’s 
demographics and general information, 
including gender, age, diabetes duration were 
collected.  
Intervention 
The intervention was carried out for four 
weeks. Subjects were given yogurt for four 
weeks at a dose of 100 mL/day. Subjects 
consumed yogurt every day in the morning or 
after the subject has breakfast. Researchers will 
give yogurt to the subject's house once a week 
and dig up data on food intake (24-hour recall 
questionnaire) and physical activity 
(International Physical Activity 
Questionnaire/IPAQ). To monitor whether the 
yogurt is consumed or not, the researcher also 
provides a checklist sheet for yogurt 
consumption to the subject to be filled every 
day. Food intake information was analysed with 
Nutrisurvey software to determine the intake of 
energy and macronutrients.  
The blood sample were collected twice, pre-
intervention and post-intervention. Measurement 
of fasting blood glucose and lipid profiles is 
carried out by the HiLab Diagnostic Center, 
Yogyakarta, Indonesia using the subject's blood 
serum. For this purpose, the patients were asked 
to fast for 10 to 12 hours before venipuncture. 
After 15 minutes of incubation at room 
temperature and clotting of the blood samples, 
they were centrifuged at 3500 rpm for 10 
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minutes. Fasting blood glucose (FBG) was 
measured by the Hexokinase method using 
Abbott reagent, analyse with Achitect C8000. 
Lipid profiles was measured using Sekisui 
reagent and analyzed with Achitect C8000. Total 
cholesterol (TC) was measured by the CHOD-
PAP method, HDL and LDL was measured by 
the Homogeneous Enzymatic Direct method. 
Triglyceride (TG) was measured by Glycerol 
Blanking method.  
Double blinding is done by the yogurt 
producer by sticking a blue leaf sticker and red 
strawberry sticker on the cup as product coding. 
After the intervention period was completed, the 
producers informed the researchers about the 
coding, blue leaf label stickers for conventional 
yogurt and red strawberry label stickers for 
probiotic yogurt.  
During this study, all the research ethics 
principles were respected. The study commenced 
after gaining approval from the Ethics 
Committee of Faculty of Medicine, Public 
Health, and Nursing, Universitas Gadjah Mada, 
Indonesia. Before the trial, the purpose and 
method of the study was explained to the 
participants, and informed consent was obtained 
from them. The participants entered the study 
voluntarily and could withdraw from the study at 
any time. The patients were assured of the 
confidentiality of the data. The information was 
handled using numerical codes instead of names 
and surnames. At the end of the trial, the clinic 
authorities and patients were given access to the 
results upon request. 
Statistical Methods 
All data were processed with the IBM SPSS 
version 22. Normal distribution of quantitative 
data was checked with Shapiro-Wilk. In the first 
step of analysis, demographic variables were 
evaluated using descriptive statistics. To analyze 
the significant differences of the FBG and lipid 
profiles level before and after the intervention, 
we used paired t-test (if the data is normally 
distributed) or the Wilcoxon test (if the data is 
not normally distributed) in each group. 
Results 
As many as 38 patients with type 2 diabetes 
mellitus were enrolled and 32 patients completed 
the intervention (Figure 1). Six patients were 
drop out from this study because of diarrhea 
(n=1), stopped taking both metformin and 
sulfonylurea (n=3), took simvastatin (n=1) and 
took antibiotic drug (n=1). All of the baseline 
characteristics were similar between the control 
and the intervention group (p>0,05), the data 
were presented in Table 1. 
In this study, we also examined the physical 
activity of subjects in both groups. The result 
showed that there was no difference between the 
control and the intervention groups. There were 
3 categories of physical activity namely heavy, 
medium, and mild. Table 2 showed that most of 
the subjects had heavy physical activity.  
Based on the analysis of dietary 
characteristic during intervention, weight, and 
BMI after intervention in control group, we can 
conclude that there was significant difference 
between pre and post intervention for 
carbohydrate intake, from 151.48±42.54 to 
170.99±52.16 g/d. In intervention group, there 
were significant increase of energy, protein, and 
fat intake, with p=0.023; p=0.003; p=0.034 
respectively. There were significant reductions 
in weight and BMI. Both control and 
intervention group had a decreased weight and 
BMI with p=0.003; p=0.002; p=0.007; p=0.005 
respectively. The data were shown in Table 3. 
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Figure 1. Schematic diagram of the subjects screening, recruitment, and intervention. 
Table 1. Subjects’ characteristics at baseline. 
 Group  
Variable Control Intervention p 
Gender Male 5 (31.3%) 5 (31.3%) 1.000a 
  Female 11 (68.8%) 11 (68.8%)  
Smoking Habits Yes  0 (0%) 3 (18.8%) 0.113b 
  No 16 (100%) 13 (81.3%)  
Yes 11 (68.8%) 12 (75%) 0.500b Metformin 
Consumption No 5 (31.3%) 4 (25%)  
Yes 9 (56.3%) 8 (50%) 0.723a Sulfonylurea 
Consumption No 7 (43.8%) 8 (50%)  
Yes  13 (81.3%) 10 (62.5%) 0.217b 
Drug compliance No 3 (18.8%) 6 (37.5%)  
Yes 2 (12.5%) 5 (31.3%) 0.197b 
Hypertension Status No 14 (87.5%) 11 (68.8%)  
Age (years)   53 (10) 56 (7) 0.290
d 
BMI   27.74 ± 3.16 27.62 ± 4.58 0.929
c 
Duration of Diabetes 
(months)   48 (36) 30 (60) 0.985
d 
Weight (kg)   64.65 (14.6) 67.20 (10.8) 0.910d 
Total Energy Intake 
(kcal)   1066.71 ±  288.88 1114.78 ± 296.98 0.646
c 
Protein Intake (gram)   30.68 (12.55) 30.58 (24.15) 0.895d 
 Carbohydrate Intake 
(gram)   151.48 ± 42.54 158.91 ± 45.94 0.638
c 
Fat Intake (gram)   34.98 (17.75) 33.1 (29.9) 0.651d 
Dietary Fiber Intake 
(gram)   6.93 (3.01) 7.90 (7.54) 0.706
d 
Cholesterol Intake 
(mg)   82.78 (136.78) 51.48 (171.98) 0.624
d 
 
The data were presented as mean + standard deviation or median (IQR) achi square, bfisher’s exact test, cIndependent t-
test, dmann-whitney 
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Table 2. Physical activity (METs) and Category of Physical activity (CP) 
 Control Intervention  p  
Physical activity (METs) 3885.4 (2109.2) 4280.6 (2553.9) 0.706a 
Heavy 13 (81.3%) 13 (81.3%) 
Medium 2 (12.5%) 3 (18.8%) 
0.934b CP 
Mild 1 (6.3%) 0 (0%)  
 
a= Mann-Whitney test  b= Kruskal Wallis test 
Table 3. Food intake characteristic of the subjects in conventional and probiotic groups before and after intervention 
Control Intervention p’’  Variable Pre Post Pre  Post  
Energy (kcal) 1066.71 ± 288.88 1190.74 ± 331.56 1114.78 ± 296.98 1349.28 ± 502.02 
p’ 0.078a 0.023a* 0.300
d 
Protein (g) 30.68 (12.55) 35.54 (14.42) 30.58 (24.15) 45.04 (19.71) 
p’ 0.326b 0.003b* 0.040
c* 
Carbohydrate (g)  151.48 ±  42.54 170.99 ± 52.16 158.91 ± 45.94 187.81 ± 63.65 
p’ 0.037a* 0.079a 0.420
d 
Fat (g) 34.98 (17.75) 42.76 (18) 33.1 (29.9) 41.28 (19.46) 
p’ 0.326b 0.034b* 0.970
c 
Dietary fiber (g) 6.93 (3.01) 7.63 (4.99) 7.9 (7.54) 8.46 (4.02) 
p’ 0.469b 0.959b 0.651
c 
Cholesterol 82.78 (136.78) 121.67 (124.82) 51.48 (171.98) 158.21 (199.71) 
p’ 0.148b 0.070b 0.624
c 
SFA (g) 17.25 (7.04) 19.06 (10.27) 16.15 (18.54) 16.53 (11.01) 
 0.737 0.717 0.678
c 
PUFA (g) 4.2 (2.21) 4.59 (3.68) 3.98 (3.64) 5.3 (5.01) 
 0.816b 0.023b* 0.534
c 
Weight 64.65 (14.58) 63.65 (13.88) 67.2 (10.8) 66.2 (10.53) 
p’ 0.003 0.007 0.806
c 
BMI 27.74±3.16 27.33 ±2.99 27.62 ±4.58 27.3 ±4.46 
p’ 0.002 0.005 0.981
d 
aPaired-Sample T test  bWilcoxon test cMann-Whitney test   cIndependent Sample T test 
SFA: saturated fatty acid 
PUFA: poly unsaturated fatty acid 
The data were presented as mean + standard deviation or median (IQR) 
 
Fasting blood glucose data was analyzed 
using Wilcoxon test and showed that there was a 
significantly decrease of fasting blood glucose in 
the conventional group from 153 (79) mg/dL to 
114 (57) mg/dL (p=0.028). Meanwhile, the 
fasting blood glucose in the probiotic group is 
not significantly decreased, from 139 (144) to 
126 (100) mg/dL (p=0.173). In the intervention 
group, the mean cholesterol level increase from 
165.38 ± 27.35 to 213,81 ± 30.8 mg/dL which 
was significant according to paired t-test 
(p<0.05). In the control group, there was a 
significant increase in mean cholesterol from 
155.25±35.52 to 193.19±42.03 mg/dL with 
p<0.001. There was no significant difference in 
LDL level between pre and post-test for control 
and intervention groups. The p-value for the pre-
test and post-test of  the control and intervention 
group are p=0.098, p=0.570 respectively. Further 
analysis was conducted, the Wilcoxon test 
described that there was a significant difference 
between the HDL level before and after 
intervention in control and intervention group 
(p=0.011, p=0.001 respectively). In this study, 
there was no significant difference (p> 0.05) in 
the triglyceride (TG) level before and after 
intervention for control and intervention group. 
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Table 4. Fasting Blood Glucose and Lipids Profile Levels. 
Group 
Control Intervention Variable 
Pre Test Post Test P Pre Test Post Test p 
FBG (mg/dL) 153 (79.25) 114.5 (56.5) 0.028b* 139.5 (144)  126 (99.75)  0.173b 
TC 
(mg/dL) 165.38±27.35
 213.81±30.81 <0.001a* 155.25±35.52  193.19±42.03  <0.001a* 
HDL (mg/dL) 37.75 (11.95) 41.80 (6.98) 0.011b* 36.60 (7.73) 41.30 (11.35) 0.001b* 
LDL (mg/dL) 128 (40)  148.5 (39)  0.098b 130 (62)  120.5 (55)  0.570b 
TG   (mg/dL) 133.5 (87)  137 (82)  0.737b 144 (87)  159.5 (102)  0.737b 
aPaired-Sample T test    bWilcoxon test 
The data were presented as mean + standard deviation or median (IQR) 
 
Discussion 
We investigated the effect of probiotic 
yogurt and conventional yogurt on fasting blood 
glucose (FBG) and lipid profiles in type 2 
diabetes mellitus patients (T2DM). The results 
showed that the FBG level was decreased in 
each group, but the control group had a higher 
reduction in FBG compared with the 
intervention group. Many previous studies 
concluded that consuming of yogurt could 
improve of the gut microbiota balance, by 
increasing gram-positive bacteria. This might be 
the main possible mechanisms on the lowering 
blood glucose in T2DM patients. The increased 
of gram-positive bacteria could decrease of gram 
negative bacteria, so it could reduce 
lipopolysaccharide (LPS) levels, and then could 
decreased of Toll- like receptor-4 (TLR4) as a 
cause of inflammation and damage to cells β 
pancreass [16].  
 Short chain fatty acid (SCFA) production 
by probiotic bacteria also may take a role as 
reducing proinflammatory marker and increasing 
glucagon-like peptide-1 (GLP-1) secretion, 
which is linked to improve insulin secretion and 
glucose uptake [17]. Probiotic bacteria could 
also increase antioxidant activity through 
increased erythrocyte superoxide dismutase 
(ESD) activity, glutathione peroxidase, and total 
antioxidants, hence it could decrease of 
oxidative stress in people with T2DM. Probiotic 
bacteria such as Lactobacillus acidophilus also 
capable to prevent oxidative damage induced by 
streptozotocin (STZ) in the pancreas by 
inhibiting lipid peroxidation and nitric-oxid 
formation [18].  
Streptococcus thermophilus and 
Lactobacillus bulgaricus have biosynthesis 
ability, like gamma-aminobutyric acid (GABA), 
that is a neurotransmitter produced by the 
pancreas. GABA can regenerate and prevent 
apoptosis in β-cell pancreas, leading to the 
improvement of insulin resistance condition in 
T2DM patients [19]. 
In the present study, the control group had a 
higher reduction in fasting blood glucose 
compared with the intervention group. This 
might be due to the viability of Bifidobacterium, 
an anaerob bacteria, in probiotic yogurt may 
depend on oxygen concentration [20]. The type 
of packaging material is also considered in the 
loss of viability of these bacteria. The material 
should be oxygen impermeable, such as glass 
bottle or high-density polyethylene (HDPE) 
packaging which can protect Bifidobacterium 
from oxygen toxicity [21]. Unfortunately, the 
packaging that was used in this study was a 
plastic cup, which is permeable to oxygen. On 
the other hand, there might be a negative 
interaction between S. thermophilus and 
Bifidobacterium. Post-fermentation acidification 
from S. thermophilus can adversely affect the 
viability of Bifidobacterium during and after 
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fermentation, resulting in lower viability of 
Bifidobacterium during storage [22]. Decreasing 
Bifidobacterium in probiotic yogurt may reduce 
its health benefit. 
We found that there was a significant 
increase of total cholesterol (TC) in both groups 
(p<0.05). In the probiotic yogurt group, there 
was an increase of TC as much as 37.94 mg/dL, 
while in the conventional yogurt group, the TC 
was increased by 48.43 mg/dL. Probiotic yogurt 
could not improve the TC levels in patients with 
type II diabetes. However, probiotic yogurt 
could control the TC levels within the normal 
range (<200 mg/dL). Conventional yogurt 
consumption increased the LDL-C levels of 
subjects in the conventional group although it 
was not statistically significant and the LDL-C 
levels still within the normal range (<150 
mg/dL). Meanwhile, probiotic yogurt 
consumption did not significantly decrease LDL-
C levels. This result is inconsistent with the 
results from previous studies reporting such 
effects in patients with type 2 diabetes and 
hypercholesterolemic patients. This discrepancy 
may be due to differences in doses of probiotics, 
interventions period, sample size, clinical 
characteristic of participants, or different study 
design [10]. According to previous study by 
Rezaei et al. [10], daily intake of 100 gram of 
probiotic yogurt containing Lactobacillus 
acidophilus La-5 and Bifidobacterium lactis BB-
12 for 4 weeks may decreased FBG and 
lowering total cholesterol. Ataei-Jafari et al. [23] 
reported that consumption 300 gram of probiotic 
yogurt everyday had a significant reduction in 
serum cholesterol level of hypercholesterolemic 
patients. Ejtahed et al. [24] also reported that 
consumption of 300 g of probiotic yogurt 
containing Lactobacillus acidophilus La-5 and 
Bifidobacterium lactis BB-12 for 6 weeks in 
type II diabetes patients caused a 4.54% decrease 
in total cholesterol and a 7.45% decrease in LDL 
compared with the control group. Zhang et al. 
[25] conducted meta-analysis study and 
summarized that probiotic yogurt consumption 
could significantly improve glucose metabolism 
which could contribute to LDL level 
improvement in patients with type 2 diabetes 
after more than 7 weeks intervention. Hence the 
inconsistent results from this study was might be 
due to inappropriate duration of intervention. 
Meta-analysis of 18 clinical trials by Berger 
et al. [26], reporting that high fat, especially 
saturated fat, and high cholesterol intake from 
dietary showed a significant increase in serum 
total cholesterol. There is a plausible mechanism 
for the effect of dietary cholesterol on serum 
lipid concentrations. Higher total cholesterol, 
LDL, and triglycerides, as well as lower HDL, 
are known risk factors for CVD. Given that 
cholesterol is synthesized in the body, there is 
compensation for absorption of additional 
dietary cholesterol by reducing cholesterol 
synthesis [27]. Major dietary sources of 
cholesterol include egg yolks, butter, fish, 
shrimp, cheese, beef, pork, and poultry. The 
relation between dietary cholesterol and serum 
cholesterol has been estimated to be linear with 
cholesterol intake up to 600 mg/day. Studies 
have reported a nonlinear relation for intakes of 
cholesterol >600 mg/day, with little effect on 
serum lipid concentration in most people. In 
healthy adults, about 1 gram of cholesterol is 
synthesized and 0.3 gram is consumed per day. 
The body maintains a relatively constant amount 
of cholesterol (150–200 mg/dL). This is done 
mainly through controlling the level of de novo 
synthesis. Dietary intake of cholesterol in part 
regulates the level of cholesterol synthesis. Both 
of these cholesterols are then used in the 
formation of membranes and in the synthesis of 
the steroid hormones and bile acids [9]. Bile acid 
synthesis uses most of this cholesterol. 
  
Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 26 / no. 4 / 2019 389 
Consumption of conventional yogurt or 
probiotic yogurt could increase the HDL level in 
a patient with type 2 diabetes mellitus 
significantly. The increasing HDL level was 
higher in intervention group. In the study 
conducted by Sadrzadeh et al. [28] showed that 
there was no significant difference in HDL level 
between conventional yogurt group and 
probiotic yogurt group. A significant difference 
of HDL level was only observed in the control 
group which consumed milk. The beneficial 
effect observed in his study was caused by the 
consumption of milk fat containing sphingolipid. 
Therefore, we assumed that the increase of HDL 
levels observed in both groups could be caused 
by sphingolipids in yogurts and in cell 
membranes of bacteria. Sphingolipids can be 
found in lipid-rich structures and have effects on 
cholesterol metabolism and transport [29]. 
Yoghurt intake could increase the sphingolipid 
intake by 11%. There are some studies revealed 
the effect of increasing HDL levels by 
consuming yogurt disregarded to the content of 
probiotic bacteria. Mohammadshahi et al. [30] 
found that probiotic yogurt consumption could 
increase the HDL level in T2DM patient 
significantly (43.66 ± 6.80 - 50.42 ± 6.64; p = 
0.023) and may be used as an alternative 
intervention to improve dyslipidemia. The result 
from several studies can be varied because of the 
differences in the type of microorganism, and 
some limitation in the study, such as the number 
of subject and the period of intervention. 
The LDL level was decreased in the 
intervention group, whereas it increased in 
control group. The decreased of LDL level in the 
intervention group could be affect by some 
mechanisms such as bile salt deconjugation, 
cholesterol assimilation, and cholesterol 
synthesis blockade in hepar. Bile salt 
deconjugation was done by L. acidophilus La-5 
and B. animalis subsp. lactis BB-12 through bile 
salt hydrolase (BSH) activity. Cholesterol 
assimilation could be processed in gut by living 
cell of probiotics. The result of cholesterol 
assimilation was cholesterol absorption blockade 
which could increase LDL absorption from 
plasma to hepatic cells or the other cells [31]. 
Cholesterol synthesis blockade in hepar would 
happen if probiotics produced acetate, 
propionate, and butyrate from dietary fiber 
fermentation process in gut. Those SCFAs could 
induce both cholesterol synthesis blockade 
and/or deport LDL to hepar which were 
initiating reduction of plasma LDL [9]. 
In control group, the LDL level was 
increased. This could be affected by saturated 
fatty acids (SFA) intake [32,33]. High SFA diet 
could reduce the catabolism of LDL apoB-100 
fractional, hence it will increase plasma LDL 
levels, however this effect is very dependent on 
types of saturated fatty acids consumed [34]. 
Intake of SFA could induce the increase of 
activity and concentration of CETP. Increase of 
plasma CETP concentrations caused an elevation 
in plasma LDL-C concentration [35].  
Abnormality of TG level on T2DM patients, 
can be affected by insulin resistance. Insulin 
resistance associated with lipoprotein lipase 
(LPL) dysfunction. LPL is an important enzyme 
for removal of TG from plasma, so impaired 
LPL is the main cause of hypertriglyceridemia in 
T2DM patient [36,37]. Insulin resistance also 
induce the lipolysis and release of plasma non- 
esterified fatty acid (NEFA) from adipose tissue 
[38], and approximately 60% of hepatic 
triglycerides are derived from plasma NEFA 
[39].  
On the other hand, butyric acid, one of short 
chain fatty acids (SCFA) produced by probiotic 
bacteria [40], is capable to suppress cyclic 
adenosine activitymonophosphate (cAMP), and 
protein kinase A (PKA) in adipocyte tissue, 
which could affect the decrease of lipase activity 
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such as adipose triglycerides lipase (ATGL) and 
hormone-sensitive lipase (HSL), which could 
reduce the lipolysis in adipocyte tissue [41]. 
Decreased of lipolysis could reduce the levels of 
NEFA, furthermore could reduce TG synthesis 
in the liver, reduce Apo B secretion, and reduce 
VLDL secretion which is rich in TG, hence 
probiotic yogurt could repair the TG level [42].  
In control group, there was a significant 
increase in carbohydrate intake (p = 0.039). The 
increase level of TG on control group could 
influenced by diet [43]. Carbohydrates intake 
could contribute to the development insulin 
resistance and diabetes mellitus [44]. High 
carbohydrate induces the hepatocytes 
triglyceride (HPTG) from overproduction of 
VLDL-TG, and cause reduced clearance of 
VLDL-TG [45]. The sources of fatty acids that 
used in HPTG synthesis could come from fatty 
acids derived from the de novo lipogenesis 
pathway because the carbohydrates can be 
converted to fatty acids through the process of de 
novo lipogenesis [46]. Jung and Choi [47] also 
reported that consumption of high carbohydrates 
(HC) meal that contains 79.1% of carbohydrates 
was associated with an increased of TG level 
after consumption HC meal (39.9 mg/dL 
increased after 2 hours and 109 mg/dL after 4 
hours).  
Previous study showed that 
hypertriglyceridemia was not associated with 
dietary fiber intake on diabetic subjects, and high 
protein-low fat (HP–LF) diet with a protein to fat 
ratio of 1.5 could improve TG concentrations 
compared with a low protein-high fat (LP–HF) 
diet on obese subjects with newly diagnosed 
type 2 diabetes mellitus [48,49].  
Conclusion 
Consumption of 100 mL/day conventional 
yogurt could significantly reduce the fasting 
blood glucose (FBG) level, whereas probiotic 
yogurt could not reduce FBG significantly. Both 
type of yogurt could improve HDL-C level. 
Hence, they can be recommended as a functional 
food for patients with type 2 diabetes mellitus.  
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